Achieving Healthcare System Readiness and Capacity for Radioligand Therapy

0

On behalf of MEP Niels Geuking (EPP, Germany), we would like to cordially invite you to attend a public working session on preparing European infrastructure and healthcare systems for the latest advances in cancer care. This event will present research conducted by IQVIA Institute for Human Data Science on “The State of Radioligand Therapy Readiness in Europe,” with funding from Novartis.

Radioligand therapy (RLT) is revolutionising cancer treatment, offering targeted solutions for various cancers, including gastroenteropancreatic neuroendocrine tumors and prostate cancer. As this innovative approach gains momentum, it’s crucial to ensure healthcare systems are prepared to deliver RLT effectively across Europe, timely and equitably.

IQVIA Institute research in Dec 2023 aimed to scope out these levers and begin identifying the capacity for RLTs in different European countries.

On 11 April, together with Members of the European Parliament (MEPs), European Commission representatives, Nuclear Medicine Physicians, Nuclear Medicine Associations and Patient Association Leaders, we will promote a discussion intended to develop a pathway to achieving capacity and readiness for RLT for cancer treatment.

The main discussion will focus on actions and policies that are needed to overcome the key barriers that constrain the use of radioligand therapy currently across the European Union.

Confirmed Speakers:

  • Jean-Yves Blay, MD, Ph.D., Professor of Medical Oncology and Director, Centre Leon Berard EURACAN ERN LYRICAN, President, Unicancer
  • Frederic Courbon, MD, President of the French Society of Nuclear Medicine and Professor of Medicine at Toulouse University Institute of Cancer
  • Ulla Engelmann, Ph.D., Director, Nuclear Safety and Security, European Commission Joint Research Centre JRC
  • Paola Anna Erba, MD, Ph.D., Associate Professor of Nuclear Medicine for the Department of Medicine and Surgery at University of Milan Bicocca and President Elect, European Association of Nuclear Medicine (EANM)
  • Eric Guedj, MD, Ph.D., Chef de Service, Nuclear Medicine and Public Assistance at Marseille Hospital
  • Nikie Jervis, International Neuroendocrine Cancer Alliance (INCA) Representative and Patient Engagement, Education & Policy Lead, Neuroendocrine Cancer UK
  • Bengt Jönsson, Ph.D., Professor Emeritus on Economics at Stockholm School of Economics
  • Jasminka Taleska, Global Director on RLT Policy Strategy at Novartis

Moderator:

Murray Aitken, Executive Director

IQVIA Institute for Human Data Science

This event will take place in person at the European Parliament in Brussels and online. Register your interest here.


link

Leave a Reply

Your email address will not be published. Required fields are marked *